awmsg logo



lopinavir/ritonavir (Kaletra®)


Reference No. 3557

Publication date:
06/03/2018


Appraisal information

lopinavir/ritonavir (Kaletra®) 80 mg/20 mg oral solution


Company: AbbVie Ltd
BNF category: Infections
NMG meeting date: 10/01/2018
AWMSG meeting date: 14/02/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0218
Ratification by Welsh Government: 05/03/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Lopinavir/ritonavir (Kaletra®) is recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Final Appraisal Recommendation (FAR)
Download